t-butyl 4-((5-formylpyridin-2-yl)oxy)piperidine-1-carboxylate | 918535-59-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: t-butyl 4-((5-formylpyridin-2-yl)oxy)piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-(5-formylpyridin-2-yl)oxypiperidine-1-carboxylate；tert-butyl 4-(5-formylpyridin-2-yl)oxypiperidine-1-carboxylate
• CAS: 918535-59-8
• 化学式: C₁₆H₂₂N₂O₄
• 分子量: 306.362
• InChiKey: AEOXPSKFIOXIRI-UHFFFAOYSA-N

物化性质

• 沸点：
  439.3±45.0 °C(Predicted)
• 密度：
  1.182±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  68.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  t-butyl 4-((5-formylpyridin-2-yl)oxy)piperidine-1-carboxylate 在 吡啶 、 盐酸羟胺 作用下， 生成 4-(5-cyano-pyridin-2-yloxy)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2007/1975

  摘要：

  公开号：
• 作为产物：
  描述：

  2-羟基吡啶-5-醛 、 N-Boc-4-碘哌啶 在 silver carbonate 作用下， 以 正庚烷 为溶剂， 反应 1.17h， 以30%的产率得到t-butyl 4-((5-formylpyridin-2-yl)oxy)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS
  [FR] MULTIPLES A(NTA)GONISTES DE D2/ANTAGONISTES DE H3 POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS AU SNC

  摘要：

  本发明涉及按照式（III）的化合物；以及其药学上可接受的盐、水合物和溶剂合物。这些化合物具有D2受体拮抗/(部分)激动剂效应和H3拮抗效应，以及其药物组合物，以及将其用于预防或治疗中枢神经系统疾病的方法。

  公开号：

  WO2015069110A1

文献信息

• Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
  申请人：Aslanian G. Robert

  公开号：US20070015807A1

  公开（公告）日：2007-01-18

  Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M 1 and M 3 are CH or N; M 2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH 2 ) q —, —C(═NOR 7 )— or —SO 1-2 —; Z is a bond or optionally substituted alkylene or alkenylene; R 1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R 2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R 3 is H, —C(O)NH 2 , or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other agents.
• HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS
  申请人：Aslanian Robert G.

  公开号：US20090286830A1

  公开（公告）日：2009-11-19

  Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M 1 and M 3 are CH or N; M 2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH 2 ) q —, —C(═NOR 7 )— or —SO 1-2 —; Z is a bond or optionally substituted alkylene or alkenylene; R 1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R 2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R 3 is H, —C(O)NH 2 , or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other agents.
• US7635705B2
  申请人：——

  公开号：US7635705B2

  公开（公告）日：2009-12-22
• US7846946B2
  申请人：——

  公开号：US7846946B2

  公开（公告）日：2010-12-07
• [EN] PIPERIDINE DERIVATIVES USEFUL AS?HISTAMINE H3 ANTAGONISTS<br/>[FR] DÉRIVÉS DE LA PIPÉRIDINE UTILES COMME ANTAGONISTES DU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：SCHERING CORP

  公开号：WO2007001975A1

  公开（公告）日：2007-01-04

  [EN] Disclosed are novel compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein: M¹ and M³ are CH or N; M² is CH, CF or N; Y is -C(=O)-, -C(=S)-, -(CH₂)_q-, -C(=NOR⁷)- or -SO_1-2-; Z is a bond or optionally substituted alkylene or alkenylene; R¹ is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula (II) where ring A is a heteroaryl ring; R² is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R³ is H, -C(O)NH₂, or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other agents.
  [FR] L'invention concerne de nouveaux composés de formule (I) ou des sels acceptables du point de vue pharmaceutique de ceux-ci, dans laquelle formule : M¹ et M³ sont CH ou N ; M² est CH, CF ou N ; Y est -C(=O)-, -C(=S)-, -(CH₂)_q-, -C(=NOR⁷)- ou -SO_1-2- ; Z est une liaison ou un alkylène ou alcénylène facultativement substitué ; R¹ est H ou un alkyle, cycloalkyle, aryle, hétéroaryle, hétérocycloalkyle, tous facultativement substitués, ou un groupe de formule (II) où le cycle A est un cycle hétéroaryle ; R² est un alkyle, alcényle, aryle, hétéroaryle, cycloalkyle ou hétérocycloalkyle facultativement substitué; R³ est H, -C(O)NH₂ ou un alkyle, aryle, cycloalkyle, hétérocycloalkyle ou hétéroaryle, tous facultativement substitués ; et les variables restantes sont telles que définies dans la description ; des compositions et procédés de traitement de réactions des voies respiratoires induites par des allergies, de la congestion, de l'obésité, d'un syndrome métabolique, de la stéatose hépatique alcoolique, de la stéatose hépatique, de la stéatose hépatique non alcoolique, de la cirrhose, du cancer primitif du foie et de troubles liés à une déficience de la cognition utilisant lesdits composés, seuls ou en association avec d'autres agents.